Screener
Arcutis Biotherapeutics, Inc. ARQT Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
FAQ
- What is Arcutis Biotherapeutics, Inc.'s total liabilities?
- Arcutis Biotherapeutics, Inc. (ARQT) reported total liabilities of $267.96M in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s total liabilities changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s total liabilities increased by 25.5% year-over-year, from $213.46M to $267.96M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s total liabilities has grown at a 54.5% compound annual growth rate (CAGR), from $27.65M to $243.49M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Arcutis Biotherapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude